Proteolytically derived endogenous angioinhibitors originating from the extracellular matrix

Pharmaceuticals

Volumn 4, Issue 12, 2011, Pages 1551-1577

  Boosani, Chandra Shekhar ^a   Sudhakar, Yakkanti A ^a,b  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiostatin; Arresten; Canstatin; Endogenous angioinhibitors; Endorepellin; Endostatin; Extracelluar matrix; Integrin signaling; PEX domain; Prothrombin kringle domain 2; Thrombospondin; Tumor angiogenesis; Tumstatin; Vasohibin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CANSTATIN; ENDOREPELLIN; ENDOSTATIN; HEXASTATIN; INTEGRIN; METICRANE; PEX PROTEIN; PROTHROMBIN KRINGLE 2; THROMBOSPONDIN; TUMSTATIN; UNCLASSIFIED DRUG; VASOHIBIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL SURVIVAL; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INTRACELLULAR SIGNALING; NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY MECHANISM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TUMOR CELL;

EID: 84855262933     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4121551     Document Type: Review

References (154)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
2. Abdollahi, A.; Lipson, K.E.; Sckell, A.; Zieher, H.; Klenke, F.; Poerschke, D.; Roth, A.; Han, X.; Krix, M.; Bischof, M, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003, 63, 8890-8898.
3. Filleur, S.; Volpert, O.V.; Degeorges, A.; Voland, C.; Reiher, F.; Clezardin, P.; Bouck, N.; Cabon, F. In vivo mechanisms by which tumors producing thrombospondin-1 bypass its inhibitory effects. Genes Dev. 2001, 15, 1373-1382.
4. Filleur, S.; Courtin, A.; Ait-Si-Ali, S.; Guglielmi, J.; Merle, C.; Harel-Bellan, A.; Clezardin, P.; Cabon, F. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003, 63, 3919-3922.
5. Fernando, N.T.; Koch, M.; Rothrock, C.; Gollogly, L.K.; D'Amore, P.A.; Ryeom, S.; Yoon, S.S. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 2008, 14, 1529-1539.
6. Colorado, P.C.; Torre, A.; Kamphaus, G.; Maeshima, Y.; Hopfer, H.; Takahashi, K.; Volk, R.; Zamborsky, E.D.; Herman, S.; Sarkar, P.K, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000, 60, 2520-2526.
7. Sudhakar, A.; Nyberg, P.; Keshamouni, V.G.; Mannam, A.P.; Li, J.; Sugimoto, H.; Cosgrove, D.; Kalluri, R. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J. Clin. Invest. 2005, 115, 2801-2810.
8. Nyberg, P.; Xie, L.; Sugimoto, H.; Colorado, P.; Sund, M.; Holthaus, K.; Sudhakar, A.; Salo, T.; Kalluri, R. Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor. Exp. Cell Res. 2008, 314, 3292-3305.
9. Boosani, C.S.; Nalabothula, N.; Sheibani, N.; Sudhakar, A. Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells. Curr. Eye Res. 2010, 35, 45-55.
10. Boosani, C.S.; Nalabothula, N.; Munugalavadla, V.; Cosgrove, D.; Keshamoun, V.G.; Sheibani, N.; Sudhakar, A. Fak and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by α1(IV)NC1. Invest. Ophthalmol. Vis. Sci. 2009, 50, 4567-4575.
11. Kamphaus, G.D.; Colorado, P.C.; Panka, D.J.; Hopfer, H.; Ramchandran, R.; Torre, A.; Maeshima, Y.; Mier, J.W.; Sukhatme, V.P.; Kalluri, R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 2000, 275, 1209-1215.
12. Magnon, C.; Galaup, A.; Mullan, B.; Rouffiac, V.; Bouquet, C.; Bidart, J.M.; Griscelli, F.; Opolon, P.; Perricaudet, M. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αVβ3 and αVβ5 integrins. Cancer Res. 2005, 65, 4353-4361.
13. Panka, D.J.; Mier, J.W. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 2003, 278, 37632-37636.
14. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C, et al. Inhibition of death receptor signals by cellular flip. Nature 1997, 388, 190-195.
15. He, G.A.; Luo, J.X.; Zhang, T.Y.; Wang, F.Y.; Li, R.F. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem. Biophys. Res. Commun. 2003, 312, 801-805.
16. He, G.A.; Luo, J.X.; Zhang, T.Y.; Hu, Z.S.; Wang, F.Y. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem. Biophys. Res. Commun. 2004, 318, 354-360.
17. Magnon, C.; Opolon, P.; Ricard, M.; Connault, E.; Ardouin, P.; Galaup, A.; Metivier, D.; Bidart, J.M.; Germain, S.; Perricaudet, M, et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1α-mediated tumor apoptotic switch. J. Clin. Invest. 2007, 117, 1844-1855.
18. Hwang-Bo, J.; Yoo, K.H.; Jeong, H.S.; Chung, I.S. Recombinant canstatin inhibits tumor growth in an orthotopic AT-84 oral squamous cell carcinoma model. Biotechnol. Lett. 2010, 32, 189-194.
19. He, X.P.; Su, C.Q.; Wang, X.H.; Pan, X.; Tu, Z.X.; Gong, Y.F.; Gao, J.; Liao, Z.; Jin, J.; Wu, H.Y, et al. E1B-55kd-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 2009, 285, 89-98.
20. Wang, W.B.; Zhou, Y.L.; Heng, D.F.; Miao, C.H.; Cao, Y.L. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Breast Cancer Res. Treat. 2008, 110, 283-295.
21. Wang, Y.; Yin, H.; Chen, P.; Xie, L. Inhibitory effect of canstatin in alkali burn-induced corneal neovascularization. Ophthalmic Res. 2011, 46, 66-72.
22. Maeshima, Y.; Colorado, P.C.; Torre, A.; Holthaus, K.A.; Grunkemeyer, J.A.; Ericksen, M.B.; Hopfer, H.; Xiao, Y.; Stillman, I.E.; Kalluri, R. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 2000, 275, 21340-21348.
23. Monboisse, J.C.; Garnotel, R.; Bellon, G.; Ohno, N.; Perreau, C.; Borel, J.P.; Kefalides, N.A. The α3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J. Biol. Chem. 1994, 269, 25475-25482.
24. Maeshima, Y.; Manfredi, M.; Reimer, C.; Holthaus, K.A.; Hopfer, H.; Chandamuri, B.R.; Kharbanda, S.; Kalluri, R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 2001, 276, 15240-15248.
25. Maeshima, Y.; Colorado, P.C.; Kalluri, R. Two RGD-independent αVβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 2000, 275, 23745-23750.
26. Maeshima, Y.; Sudhakar, A.; Lively, J.C.; Ueki, K.; Kharbanda, S.; Kahn, C.R.; Sonenberg, N.; Hynes, R.O.; Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295, 140-143.
27. Han, J.; Ohno, N.; Pasco, S.; Monboisse, J.C.; Borel, J.P.; Kefalides, N.A. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J. Biol. Chem. 1997, 272, 20395-20401.
28. Kawaguchi, T.; Yamashita, Y.; Kanamori, M.; Endersby, R.; Bankiewicz, K.S.; Baker, S.J.; Bergers, G.; Pieper, R.O. The PTEN/Akt pathway dictates the direct αVβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 2006, 66, 11331-11340.
29. Xie, L.; Duncan, M.B.; Pahler, J.; Sugimoto, H.; Martino, M.; Lively, J.; Mundel, T.; Soubasakos, M.; Rubin, K.; Takeda, T, et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc. Natl. Acad. Sci. USA 2011, 108, 9939-9944.
30. Goto, T.; Ishikawa, H.; Matsumoto, K.; Nishimura, D.; Kusaba, M.; Taura, N.; Shibata, H.; Miyaaki, H.; Ichikawa, T.; Hamasaki, K, et al. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int. J. Oncol. 2008, 33, 33-40.
31. Yan, Y.; Xu, W.; Qian, H.; Zhu, W.; Mao, F.; Zhang, X. Tumstatin45-132-TNFα suppresses tumour growth through anti-angiogenic effects and cytotoxicity. Biotechnol. Appl. Biochem. 2010, 56, 119-127.
32. Chung, I.S.; Son, Y.I.; Ko, Y.J.; Baek, C.H.; Cho, J.K.; Jeong, H.S. Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol. 2008, 44, 1118-1126.
33. Petitclerc, E.; Boutaud, A.; Prestayko, A.; Xu, J.; Sado, Y.; Ninomiya, Y.; Sarras, M.P., Jr.; Hudson, B.G.; Brooks, P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 2000, 275, 8051-8061.
34. Sudhakar, A.; Sugimoto, H.; Yang, C.; Lively, J.; Zeisberg, M.; Kalluri, R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αVβ3 and α5β1 integrins. Proc. Natl. Acad. Sci. USA 2003, 100, 4766-4771.
35. Boosani, C.S.; Mannam, A.P.; Cosgrove, D.; Silva, R.; Hodivala-Dilke, K.M.; Keshamouni, V.G.; Sudhakar, A. Regulation of COX-2 mediated signaling by α3 type IV noncollagenous domain in tumor ngiogenesis. Blood 2007, 110, 1168-1177.
36. Eikesdal, H.P.; Sugimoto, H.; Birrane, G.; Maeshima, Y.; Cooke, V.G.; Kieran, M.; Kalluri, R. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc. Natl. Acad. Sci. USA 2008, 105, 15040-15045.
37. Thevenard, J.; Ramont, L.; Devy, J.; Brassart, B.; Dupont-Deshorgue, A.; Floquet, N.; Schneider, L.; Ouchani, F.; Terryn, C.; Maquart, F.X, et al. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int. J. Cancer 2010, 126, 1055-1066.
38. Zhang, X.; Xu, W.; Qian, H.; Zhu, W.; Zhang, R. Mesenchymal stem cells modified to express lentivirus TNFα tumstatin(45-132) inhibit the growth of prostate cancer. J. Cell. Mol. Med. 2011, 15, 433-444.
39. Liu, Y.; Li, J.; Xu, H.; Zhang, Y.; Liu, X. Mitochondria-mediated tumstatin peptide-induced HepG-2 cell apoptosis. Int. J. Mol. Med. 2009, 24, 653-659.
40. Mundel, T.M.; Yliniemi, A.M.; Maeshima, Y.; Sugimoto, H.; Kieran, M.; Kalluri, R. Type IV collagen α6 chain-derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth. Int. J. Cancer 2008, 122, 1738-1744.
41. O'Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.S.; Flynn, E.; Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
42. Folkman, J. Antiangiogenesis in cancer therapy-Endostatin and its mechanisms of action. Exp. Cell Res. 2006, 312, 594-607.
43. Sertie, A.L.; Sossi, V.; Camargo, A.A.; Zatz, M.; Brahe, C.; Passos-Bueno, M.R. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum. Mol. Genet. 2000, 9, 2051-2058.
44. Suzuki, O.T.; Sertie, A.L.; Der Kaloustian, V.M.; Kok, F.; Carpenter, M.; Murray, J.; Czeizel, A.E.; Kliemann, S.E.; Rosemberg, S.; Monteiro, M, et al. Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in knobloch syndrome. Am. J. Hum. Genet. 2002, 71, 1320-1329.
45. Hefler, L.; Tempfer, C.; Kainz, C.; Obermair, A. Serum concentrations of endostatin in patients with vulvar cancer. Gynecol. Oncol. 1999, 74, 151-152.
46. Zorick, T.S.; Mustacchi, Z.; Bando, S.Y.; Zatz, M.; Moreira-Filho, C.A.; Olsen, B.; Passos-Bueno, M.R. High serum endostatin levels in down syndrome: Implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 2001, 9, 811-814.
47. Kim, H.S.; Lim, S.J.; Park, Y.K. Anti-angiogenic factor endostatin in osteosarcoma. APMIS 2009, 117, 716-723.
48. Iizasa, T.; Chang, H.; Suzuki, M.; Otsuji, M.; Yokoi, S.; Chiyo, M.; Motohashi, S.; Yasufuku, K.; Sekine, Y.; Iyoda, A, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 5361-5366.
49. Hu, T.H.; Huang, C.C.; Wu, C.L.; Lin, P.R.; Liu, S.Y.; Lin, J.W.; Chuang, J.H.; Tai, M.H. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod. Pathol. 2005, 18, 663-672.
50. Hata, K.; Dhar, D.K.; Kanasaki, H.; Nakayama, K.; Fujiwaki, R.; Katabuchi, H.; Okamura, H.; Nagasue, N.; Miyazaki, K. Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res. 2003, 23, 1907-1912.
51. Guan, K.P.; Ye, H.Y.; Yan, Z.; Wang, Y.; Hou, S.K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61, 719-723.
52. Homer, J.J.; Greenman, J.; Stafford, N.D. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin. Otolaryngol. Allied Sci. 2002, 27, 32-37.
53. Feldman, A.L.; Alexander, H.R., Jr.; Yang, J.C.; Linehan, W.M.; Eyler, R.A.; Miller, M.S.; Steinberg, S.M.; Libutti, S.K. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002, 95, 1637-1643.
54. Feldman, A.L.; Pak, H.; Yang, J.C.; Alexander, H.R., Jr.; Libutti, S.K. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001, 91, 1525-1529.
55. Wrobel, T.; Mazur, G.; Kapelko, K.; Kuliczkowski, K. Endostatin serum level in acute myeloid leukemia. Neoplasma 2005, 52, 182-184.
56. Feldman, A.L.; Alexander, H.R., Jr.; Bartlett, D.L.; Kranda, K.C.; Miller, M.S.; Costouros, N.G.; Choyke, P.L.; Libutti, S.K. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann. Surg. Oncol. 2001, 8, 741-745.
57. Felbor, U.; Dreier, L.; Bryant, R.A.; Ploegh, H.L.; Olsen, B.R.; Mothes, W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000, 19, 1187-1194.
58. Fang, J.; Shing, Y.; Wiederschain, D.; Yan, L.; Butterfield, C.; Jackson, G.; Harper, J.; Tamvakopoulos, G.; Moses, M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA 2000, 97, 3884-3889.
59. Itoh, Y.; Ito, A.; Iwata, K.; Tanzawa, K.; Mori, Y.; Nagase, H. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase a) activated on the cell surface. J. Biol. Chem. 1998, 273, 24360-24367.
60. Kim, Y.M.; Jang, J.W.; Lee, O.H.; Yeon, J.; Choi, E.Y.; Kim, K.W.; Lee, S.T.; Kwon, Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000, 60, 5410-5413.
61. Hajitou, A.; Grignet, C.; Devy, L.; Berndt, S.; Blacher, S.; Deroanne, C.F.; Bajou, K.; Fong, T.; Chiang, Y.; Foidart, J.M, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002, 16, 1802-1804.
62. Kim, T.H.; Kim, E.; Yoon, D.; Kim, J.; Rhim, T.Y.; Kim, S.S. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit lewis lung carcinoma tumor growth and metastases. Angiogenesis 2002, 5, 191-201.
63. Skovseth, D.K.; Veuger, M.J.; Sorensen, D.R.; de Angelis, P.M.; Haraldsen, G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005, 105, 1044-1051.
64. Abdollahi, A.; Hahnfeldt, P.; Maercker, C.; Grone, H.J.; Debus, J.; Ansorge, W.; Folkman, J.; Hlatky, L.; Huber, P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 2004, 13, 649-663.
65. Shi, H.; Huang, Y.; Zhou, H.; Song, X.; Yuan, S.; Fu, Y.; Luo, Y. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110, 2899-2906.
66. Ginisty, H.; Amalric, F.; Bouvet, P. Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 1998, 17, 1476-1486.
67. Erard, M.S.; Belenguer, P.; Caizergues-Ferrer, M.; Pantaloni, A.; Amalric, F. A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone H1. Eur. J. Biochem. 1988, 175, 525-530.
68. Kharrat, A.; Derancourt, J.; Doree, M.; Amalric, F.; Erard, M. Synergistic effect of histone H1 and nucleolin on chromatin condensation in mitosis: Role of a phosphorylated heteromer. Biochemistry 1991, 30, 10329-10336.
69. Huang, Y.; Shi, H.; Zhou, H.; Song, X.; Yuan, S.; Luo, Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006, 107, 3564-3571.
70. Dhanabal, M.; Ramchandran, R.; Waterman, M.J.; Lu, H.; Knebelmann, B.; Segal, M.; Sukhatme, V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 1999, 274, 11721-11726.
71. Dhanabal, M.; Volk, R.; Ramchandran, R.; Simons, M.; Sukhatme, V.P. Cloning, expression, and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 1999, 258, 345-352.
72. Rehn, M.; Veikkola, T.; Kukk-Valdre, E.; Nakamura, H.; Ilmonen, M.; Lombardo, C.; Pihlajaniemi, T.; Alitalo, K.; Vuori, K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 1024-1029.
73. MacDonald, N.J.; Shivers, W.Y.; Narum, D.L.; Plum, S.M.; Wingard, J.N.; Fuhrmann, S.R.; Liang, H.; Holland-Linn, J.; Chen, D.H.; Sim, B.K. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 2001, 276, 25190-25196.
74. Sund, M.; Hamano, Y.; Sugimoto, H.; Sudhakar, A.; Soubasakos, M.; Yerramalla, U.; Benjamin, L.E.; Lawler, J.; Kieran, M.; Shah, A, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA 2005, 102, 2934-2939.
75. Mongiat, M.; Sweeney, S.M.; San Antonio, J.D.; Fu, J.; Iozzo, R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278, 4238-4249.
76. Gonzalez, E.M.; Reed, C.C.; Bix, G.; Fu, J.; Zhang, Y.; Gopalakrishnan, B.; Greenspan, D.S.; Iozzo, R.V. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 2005, 280, 7080-7087.
77. Cailhier, J.F.; Sirois, I.; Laplante, P.; Lepage, S.; Raymond, M.A.; Brassard, N.; Prat, A.; Iozzo, R.V.; Pshezhetsky, A.V.; Hebert, M.J. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J. Biol. Chem. 2008, 283, 27220-27229.
78. Woodall, B.P.; Nystrom, A.; Iozzo, R.A.; Eble, J.A.; Niland, S.; Krieg, T.; Eckes, B.; Pozzi, A.; Iozzo, R.V. Integrin α2β1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283, 2335-2343.
79. Bix, G.; Fu, J.; Gonzalez, E.M.; Macro, L.; Barker, A.; Campbell, S.; Zutter, M.M.; Santoro, S.A.; Kim, J.K.; Hook, M, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J. Cell Biol. 2004, 166, 97-109.
80. Laplante, P.; Raymond, M.A.; Labelle, A.; Abe, J.; Iozzo, R.V.; Hebert, M.J. Perlecan proteolysis induces an α2β1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J. Biol. Chem. 2006, 281, 30383-30392.
81. Bix, G.; Iozzo, R.A.; Woodall, B.; Burrows, M.; McQuillan, A.; Campbell, S.; Fields, G.B.; Iozzo, R.V. Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the α2β1-integrin receptor. Blood 2007, 109, 3745-3748.
82. Nystrom, A.; Shaik, Z.P.; Gullberg, D.; Krieg, T.; Eckes, B.; Zent, R.; Pozzi, A.; Iozzo, R.V. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009, 114, 4897-4906.
83. Seo, D.W.; Li, H.; Guedez, L.; Wingfield, P.T.; Diaz, T.; Salloum, R.; Wei, B.Y.; Stetler-Stevenson, W.G. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 2003, 114, 171-180.
84. Seo, D.W.; Kim, S.H.; Eom, S.H.; Yoon, H.J.; Cho, Y.R.; Kim, P.H.; Kim, Y.K.; Han, J.W.; Diaz, T.; Wei, B.Y, et al. TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc. Res. 2008, 76, 145-151
85. Hoegy, S.E.; Oh, H.R.; Corcoran, M.L.; Stetler-Stevenson, W.G. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 2001, 276, 3203-3214.
86. Corcoran, M.L.; Stetler-Stevenson, W.G. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a CAMP-dependent mechanism. J. Biol. Chem. 1995, 270, 13453-13459.
87. Goyal, A.; Pal, N.; Concannon, M.; Paul, M.; Doran, M.; Poluzzi, C.; Sekiguchi, K.; Whitelock, J.M.; Neill, T.; Iozzo, R.V. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEFGR2). A dual receptor antagonism. J. Biol. Chem. 2011, 286, 25947-25962.
88. Bix, G.; Castello, R.; Burrows, M.; Zoeller, J.J.; Weech, M.; Iozzo, R.A.; Cardi, C.; Thakur, M.L.; Barker, C.A.; Camphausen, K, et al. Endorepellin in vivo: Targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98, 1634-1646.
89. Chang, J.W.; Kang, U.B.; Kim, D.H.; Yi, J.K.; Lee, J.W.; Noh, D.Y.; Lee, C.; Yu, M.H. Identification of circulating endorepellin IG3 fragment: Potential use as a serological biomarker for breast cancer. Proteomics Clin. Appl. 2008, 2, 23-32.
90. O'Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lane, W.S.; Cao, Y.; Sage, E.H.; Folkman, J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994, 79, 315-328.
91. Gately, S.; Twardowski, P.; Stack, M.S.; Cundiff, D.L.; Grella, D.; Castellino, F.J.; Enghild, J.; Kwaan, H.C.; Lee, F.; Kramer, R.A, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 1997, 94, 10868-10872.
92. Gately, S.; Twardowski, P.; Stack, M.S.; Patrick, M.; Boggio, L.; Cundiff, D.L.; Schnaper, H.W.; Madison, L.; Volpert, O.; Bouck, N, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 1996, 56, 4887-4890.
93. Claesson-Welsh, L.; Welsh, M.; Ito, N.; Anand-Apte, B.; Soker, S.; Zetter, B.; O'Reilly, M.; Folkman, J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 1998, 95, 5579-5583.
94. Redlitz, A.; Daum, G.; Sage, E.H. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res. 1999, 36, 28-34.
95. Meneses, P.I.; Abrey, L.E.; Hajjar, K.A.; Gultekin, S.H.; Duvoisin, R.M.; Berns, K.I.; Rosenfeld, M.R. Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin. Cancer Res. 1999, 5, 3689-3694.
96. Lijnen, H.R. Pathophysiology of the plasminogen/plasmin system. Int. J. Clin. Lab. Res. 1996, 26, 1-6.
97. Moser, T.L.; Stack, M.S.; Asplin, I.; Enghild, J.J.; Hojrup, P.; Everitt, L.; Hubchak, S.; Schnaper, H.W.; Pizzo, S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 1999, 96, 2811-2816.
98. Troyanovsky, B.; Levchenko, T.; Mansson, G.; Matvijenko, O.; Holmgren, L. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 2001, 152, 1247-1254.
99. Tarui, T.; Miles, L.A.; Takada, Y. Specific interaction of angiostatin with integrin αVβ3 in endothelial cells. J. Biol. Chem. 2001, 276, 39562-39568.
100. Rhim, T.Y.; Park, C.S.; Kim, E.; Kim, S.S. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem. Biophys. Res. Commun. 1998, 252, 513-516.
101. Lee, T.H.; Rhim, T.; Kim, S.S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J. Biol. Chem. 1998, 273, 28805-28812.
102. Hwang, H.S.; Kim, D.W.; Kim, S.S. Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: Anti-proliferative activity and cellular internalization. Biochem. J. 2006, 395, 165-172.
103. Kim, T.H.; Ahn, S.; Kim, J.; Kim, I.; Yang, M.Z.; Lee, J.E.; Kim, S.S. Recombinant human prothrombin kringle-2 inhibits B16F10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression. Clin. Exp. Metastasis 2006, 23, 391-399.
104. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
105. Block, M.L.; Li, G.; Qin, L.; Wu, X.; Pei, Z.; Wang, T.; Wilson, B.; Yang, J.; Hong, J.S. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: Substance P vs. Dynorphin. FASEB J. 2006, 20, 251-258.
106. Dheen, S.T.; Kaur, C.; Ling, E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007, 14, 1189-1197.
107. Gao, H.M.; Liu, B.; Hong, J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 2003, 23, 6181-6187.
108. Moisse, K.; Strong, M.J. Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762, 1083-1093.
109. Won, S.Y.; Choi, S.H.; Jin, B.K. Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: Role of microglial NADPH oxidase. J. Neuroimmunol. 2009, 214, 83-92.
110. Kim, S.R.; Chung, E.S.; Bok, E.; Baik, H.H.; Chung, Y.C.; Won, S.Y.; Joe, E.; Kim, T.H.; Kim, S.S.; Jin, M.Y, et al. Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J. Neurosci. Res. 2010, 88, 1537-1548
111. Baenziger, N.L.; Brodie, G.N.; Majerus, P.W. A thrombin-sensitive protein of human platelet membranes. Proc. Natl. Acad. Sci. USA 1971, 68, 240-243.
112. Lawler, J.W.; Slayter, H.S.; Coligan, J.E. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem. 1978, 253, 8609-8616
113. Nor, J.E.; Mitra, R.S.; Sutorik, M.M.; Mooney, D.J.; Castle, V.P.; Polverini, P.J. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J. Vasc. Res. 2000, 37, 209-218.
114. Calzada, M.J.; Sipes, J.M.; Krutzsch, H.C.; Yurchenco, P.D.; Annis, D.S.; Mosher, D.F.; Roberts, D.D. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by α6β1 integrin. J. Biol. Chem. 2003, 278, 40679-40687.
115. Isenberg, J.S.; Ridnour, L.A.; Dimitry, J.; Frazier, W.A.; Wink, D.A.; Roberts, D.D. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 2006, 281, 26069-26080.
116. Isenberg, J.S.; Pappan, L.K.; Romeo, M.J.; Abu-Asab, M.; Tsokos, M.; Wink, D.A.; Frazier, W.A.; Roberts, D.D. Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann. Surg. 2008, 247, 180-190.
117. Kaur, S.; Martin-Manso, G.; Pendrak, M.L.; Garfield, S.H.; Isenberg, J.S.; Roberts, D.D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 2010, 285, 38923-38932.
118. Tucker, R.P. The thrombospondin type 1 repeat superfamily. Int. J. Biochem. Cell Biol. 2004, 36, 969-974.
119. Lawler, J.; Detmar, M. Tumor progression: The effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 2004, 36, 1038-1045.
120. Primo, L.; Ferrandi, C.; Roca, C.; Marchio, S.; di Blasio, L.; Alessio, M.; Bussolino, F. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 2005, 19, 1713-1715.
121. Short, S.M.; Derrien, A.; Narsimhan, R.P.; Lawler, J.; Ingber, D.E.; Zetter, B.R. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins. J. Cell Biol. 2005, 168, 643-653.
122. Jimenez, B.; Volpert, O.V.; Crawford, S.E.; Febbraio, M.; Silverstein, R.L.; Bouck, N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 2000, 6, 41-48.
123. Jimenez, B.; Volpert, O.V.; Reiher, F.; Chang, L.; Munoz, A.; Karin, M.; Bouck, N. c-jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 2001, 20, 3443-3448.
124. Bogdanov, A., Jr.; Marecos, E.; Cheng, H.C.; Chandrasekaran, L.; Krutzsch, H.C.; Roberts, D.D.; Weissleder, R. Treatment of experimental brain tumors with trombospondin-1 derived peptides: An in vivo imaging study. Neoplasia 1999, 1, 438-445.
125. Guo, N.; Krutzsch, H.C.; Inman, J.K.; Roberts, D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997, 57, 1735-1742.
126. Shafiee, A.; Penn, J.S.; Krutzsch, H.C.; Inman, J.K.; Roberts, D.D.; Blake, D.A. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest. Ophthalmol. Vis. Sci. 2000, 41, 2378-2388.
127. Bein, K.; Simons, M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 2000, 275, 32167-32173
128. Rodriguez-Manzaneque, J.C.; Lane, T.F.; Ortega, M.A.; Hynes, R.O.; Lawler, J.; Iruela-Arispe, M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 2001, 98, 12485-12490.
129. Hawighorst, T.; Velasco, P.; Streit, M.; Hong, Y.K.; Kyriakides, T.R.; Brown, L.F.; Bornstein, P.; Detmar, M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host anti-tumor defense mechanism. EMBO J. 2001, 20, 2631-2640.
130. Hawighorst, T.; Oura, H.; Streit, M.; Janes, L.; Nguyen, L.; Brown, L.F.; Oliver, G.; Jackson, D.G.; Detmar, M. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 2002, 21, 7945-7956.
131. Cursiefen, C.; Maruyama, K.; Bock, F.; Saban, D.; Sadrai, Z.; Lawler, J.; Dana, R.; Masli, S. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J. Exp. Med. 2011, 208, 1083-1092.
132. Mignatti, P.; Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993, 73, 161-195.
133. DeClerck, Y.A.; Laug, W.E. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme Protein 1996, 49, 72-84.
134. Stetler-Stevenson, W.G.; Hewitt, R.; Corcoran, M. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin. Cancer Biol. 1996, 7, 147-154
135. Brooks, P.C.; Silletti, S.; von Schalscha, T.L.; Friedlander, M.; Cheresh, D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92, 391-400.
136. Pfeifer, A.; Kessler, T.; Silletti, S.; Cheresh, D.A.; Verma, I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 2000, 97, 12227-12232.
137. Pluderi, M.; Lucini, V.; Caronzolo, D.; Pannacci, M.; Costa, F.; Carrabba, G.; Giussani, C.; Grosso, S.; Colleoni, F.; Scaglione, F.; Villani, R.; Bikfalvi, A.; Bello, L. Long-term inhibition of glioma growth by systemic administration of human PEX. J. Neurosurg. Sci. 2003, 47, 69-78
138. Kim, S.K.; Cargioli, T.G.; Machluf, M.; Yang, W.; Sun, Y.; Al-Hashem, R.; Kim, S.U.; Black, P.M.; Carroll, R.S. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin. Cancer Res. 2005, 11, 5965-5970.
139. Ezhilarasan, R.; Jadhav, U.; Mohanam, I.; Rao, J.S.; Gujrati, M.; Mohanam, S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int. J. Cancer 2009, 124, 306-315.
140. Watanabe, K.; Hasegawa, Y.; Yamashita, H.; Shimizu, K.; Ding, Y.; Abe, M.; Ohta, H.; Imagawa, K.; Hojo, K.; Maki, H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 2004, 114, 898-907.
141. Shimizu, K.; Watanabe, K.; Yamashita, H.; Abe, M.; Yoshimatsu, H.; Ohta, H.; Sonoda, H.; Sato, Y. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem. Biophys. Res. Commun. 2005, 327, 700-706.
142. Kimura, H.; Miyashita, H.; Suzuki, Y.; Kobayashi, M.; Watanabe, K.; Sonoda, H.; Ohta, H.; Fujiwara, T.; Shimosegawa, T.; Sato, Y. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 2009, 113, 4810-4818
143. Naito, H.; Kidoya, H.; Sato, Y.; Takakura, N. Induction and expression of anti-angiogenic vasohibins in the hematopoietic stem/progenitor cell population. J. Biochem. 2009, 145, 653-659
144. Yamashita, H.; Abe, M.; Watanabe, K.; Shimizu, K.; Moriya, T.; Sato, A.; Satomi, S.; Ohta, H.; Sonoda, H.; Sato, Y. Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem. Biophys. Res. Commun. 2006, 345, 919-925.
145. Yoshinaga, K.; Ito, K.; Moriya, T.; Nagase, S.; Takano, T.; Niikura, H.; Yaegashi, N.; Sato, Y. Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci. 2008, 99, 914-919.
146. Wakusawa, R.; Abe, T.; Sato, H.; Yoshida, M.; Kunikata, H.; Sato, Y.; Nishida, K. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Am. J. Ophthalmol. 2008, 146, 235-243.
147. Tamaki, K.; Moriya, T.; Sato, Y.; Ishida, T.; Maruo, Y.; Yoshinaga, K.; Ohuchi, N.; Sasano, H. Vasohibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis. Cancer Sci. 2009, 100, 88-94.
148. Sato, H.; Abe, T.; Wakusawa, R.; Asai, N.; Kunikata, H.; Ohta, H.; Sonoda, H.; Sato, Y.; Nishida, K. Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetologia 2009, 52, 359-361.
149. Sato, Y. Delta-like 4 and vasohibin 1: Two endothelium-produced negative regulators of angiogenesis with distinctive roles. Eur. Cytokine Netw. 2009, 20, 220-224.
150. Hosaka, T.; Kimura, H.; Heishi, T.; Suzuki, Y.; Miyashita, H.; Ohta, H.; Sonoda, H.; Moriya, T.; Suzuki, S.; Kondo, T, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am. J. Pathol. 2009, 175, 430-439.
151. Miyake, K.; Nishida, K.; Kadota, Y.; Yamasaki, H.; Nasu, T.; Saitou, D.; Tanabe, K.; Sonoda, H.; Sato, Y.; Maeshima, Y, et al. Inflammatory cytokine-induced expression of vasohibin-1 by rheumatoid synovial fibroblasts. Acta Med. Okayama 2009, 63, 349-358
152. Kern, J.; Steurer, M.; Gastl, G.; Gunsilius, E.; Untergasser, G. Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer 2009, 9, 284
153. Heishi, T.; Hosaka, T.; Suzuki, Y.; Miyashita, H.; Oike, Y.; Takahashi, T.; Nakamura, T.; Arioka, S.; Mitsuda, Y.; Takakura, T, et al. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am. J. Pathol. 2010, 176, 1950-1958.
154. Venancio, T.M.; DeMarco, R.; Almeida, G.T.; Oliveira, K.C.; Setubal, J.C.; Verjovski-Almeida, S. Analysis of schistosoma mansoni genes shared with deuterostomia and with possible roles in host interactions. BMC Genomics 2007, 8, 407.